| Drug Name |
Donepezil |
| Drug ID |
BADD_D00706 |
| Description |
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990.[A182411] Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia.
Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.[T668] |
| Indications and Usage |
For the palliative treatment of mild to moderate dementia of the Alzheimer's type. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N06DA02 |
| DrugBank ID |
DB00843
|
| KEGG ID |
D07869
|
| MeSH ID |
D000077265
|
| PubChem ID |
3152
|
| TTD Drug ID |
D0NS6H
|
| NDC Product Code |
65085-0046 |
| Synonyms |
Donepezil | Eranz | Donepezilium Oxalate Trihydrate | E 2020 | E2020 | E-2020 | Donepezil Hydrochloride | 1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride | Aricept |
